A Study of SKLB1028 in Patients With Advanced Solid Tumor

Advanced Solid Tumors Clinical Trial

Official title:

An Open-label, Multicenter, Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of SKLB1028 in Patients With Advanced Solid Tumors

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05072522
• Other study ID #: HA114-CSP-012
• Status: Not yet recruiting
• Phase: Phase 1
• Start date: October 2021
• Est. completion date: October 2023

Study information

• Verified date: September 2021
• Source: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
• Contact: Xuefang Xia
• Phone: +86-010-63932012
• Email: xiaxuefang[@]mail.ecspc.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of SKLB1028 in patients with advanced solid tumors.

Description:

This study is divided into two stages. The first stage is the dose-escalation stage to evaluate the safety, tolerance and pharmacokinetics of SKLB1028 in patients with advanced solid tumors. A classic 3+3 design will be used to determine the maximum tolerated dose (MTD). Patients with advanced solid tumors will receive SKLB1028 orally once daily (QD) in continuous 28-day cycles, starting at a dose of 200 mg and rising to 400 mg. The second stage is cohort-expansion study. The safe tolerated dose group will be selected for case expansion. At this stage, patients with advanced solid tumors with better response on SKLB1028 are mainly enrolled.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 98
• Est. completion date: October 2023
• Est. primary completion date: October 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients volunteered to participate in this study and signed the informed consent form.

• Age =18, no gender limitation.

• Patients with malignant solid tumor who have failed or could not tolerate standard treatment and for whom no standard treatment is available.

• Recurrent or metastatic solid tumors confirmed by histology; patients who are judged by the investigator to be suitable for treatment with SKLB1028 capsules and who meet the requirements of tumor type for corresponding stages:

1. Stage I: no restriction on solid tumor types;

2. Phase II: solid tumor type determined by the investigator and the sponsor based on the results of phase I.

• Stage 1: At least one unmeasurable lesion; Stage 2: At least one measurable lesion according to RECIST v1.1.

• Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.

• Patient must meet the following criteria as indicated on the clinical laboratory tests:

1. Absolute neutrophil count =1.5×10^9 /L; platelet count =80×10^9 /L; hemoglobin =90 g/L;

2. Serum creatinine = 1.5 × upper limit of normal (ULN);

3. Total bilirubin = 1.5 × ULN, (= 3 × ULN for patients with liver metastasis or liver cancer); Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) = 3 × ULN (= 5 × ULN for patients with liver metastasis or liver cancer).

• Patient is suitable for oral administration of the study drug.

• Female patients should agree to use contraceptive measures (such as IUD, condom, etc.) during the study period and within 6 months after the end of the study; negative serum pregnancy test within 7 days prior to enrollment and must be non-lactating patients; male patients should agree to use contraceptive measures during the study period and within 6 months after the end of the study period.

Exclusion Criteria:

• The patient have a previous history of severe allergy to drugs and food.

• Expected survival < 3 months.

• Other malignant active tumors within the past 3 years; except for cured locally curable cancers, such as basal or squamous cell skin carcinoma, or in situ prostate, cervical or breast cancer.

• Central nervous system metastasis (excluding brain metastasis with stable symptoms after local treatment)

• Patients with hepatitis B (HBsAg positive or HBcAb positive with HBV DNA higher than the upper limit of the normal value of the research center) or hepatitis C (HCV antibody positive with HCV RNA higher than the upper limit of the normal value of the research center) or HIV antibody positive.

• Patients whose toxicity of previous anti-tumor treatment has not recovered to = grade 1.

• Cardiac dysfunction, including:

QTc interval female = 470 ms, male = 450 ms; Complete left bundle branch block, grade II or III atrioventricular block; Poorly controlled malignant arrhythmias; Cardiac valve regurgitation or stenosis requiring treatment; Cardiac ejection fraction less than 50% within 6 months before screening; Myocardial infarction, unstable angina pectoris, severe pericardial disease, severe myocardial disease occurred within 6 months before screening; History of chronic congestive heart failure with NYHA = grade 3.

• Patients have poorly controlled hypertension.

• Patients have thrombotic or embolic events such as cerebrovascular accident, pulmonary embolism, etc within 6 months before screening.

• Patients who have received any antitumor treatment within 4 weeks before the first administration; those who have received herbal or proprietary Chinese medicines with a clear antineoplastic indication 2 weeks prior to the first administration.

• Patients have received other unlisted clinical study drugs within 4 weeks before the first administration.

Related Conditions & MeSH terms

• Advanced Solid Tumors
• Neoplasms

Intervention

Drug:
• SKLB1028
SKLB1028 capsules, oral, once daily in continuous 28-day cycles

Locations

Country	Name	City	State
China	Henan Cancer Hospital	Zhengzhou	Henan

Sponsors (1)

Lead Sponsor	Collaborator
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Dose limiting toxicity (DLT)	To identify the dose-limited toxicity (DLT).	At the end of Cycle 1 (each cycle is 28 days)
Primary	Maximum tolerated dose (MTD)	To identify the maximum tolerated dose (MTD)	At the end of Cycle 1 (each cycle is 28 days)
Primary	Treatment Emergent Adverse Event (TEAE)	TEAE is defined as an adverse event that occurs during treatment	From the initiation of the first dose to 28 days after the last dose
Secondary	Pharmacokinetic indexes, Cmax	Maximum concentration (Cmax) of SKLB1028	At the end of Cycle 1 (each cycle is 28 days)
Secondary	Pharmacokinetic indexes, Tmax Pharmacokinetic indexes, Tmax	Time to Cmax (Tmax) of SKLB1028	At the end of Cycle 1 (each cycle is 28 days)
Secondary	Pharmacokinetic indexes, AUC0-t	Area under the concentration-time curve (AUC) from 0 to the last measurable concentration (AUC0-t) of SKLB1028	At the end of Cycle 1 (each cycle is 28 days)
Secondary	Overall response rate (ORR)	ORR is defined as the proportion of patients who have a best overall response of complete response (CR) or partial response (PR) as per Response Evaluation Criteria In Solid Tumors (RECIST) 1.1.	Up to approximately 2 years
Secondary	Progression-free survival (PFS)	PFS is defined as the time from the date of first dose until the date of first documented PD as per RECIST 1.1 or death from any cause, whichever occurs first	Up to approximately 2 years
Secondary	Disease control rate (DCR)	DCR is defined as the proportion of patients who have a response of CR/PR or stable disease (SD) as per RECIST 1.1	Up to approximately 2 years
Secondary	Duration of response (DOR)	DoR is defined as the time from the first assessment of CR or PR until the date of first occurrence of progressive disease (PD) as per RECIST 1.1 or death from any cause, whichever occurs first	Up to approximately 2 years